Global Physician Survey Highlights Need For Improved Management Of GERD Patients
The research, which was conducted by market research consultants CLEAR Ideas, in association with AstraZeneca, mapped how physicians perceive clinical and emotional needs of GERD patients. Physicians from France, Germany, Italy, the United States and the United Kingdom reviewed more than 3000 GERD patient records.
The results revealed that physicians make a clear distinction between different types of GERD patients and recognise that patients with GERD have different therapeutic requirements. Their classification is used in treatment decisions and based primarily on physical impact but also psychological factors (stress and anxiety), allowing three broad groups to be described:
--- Patients suffering from 'long term, disrupting GERD'
Having higher physical but also psychological impact: Patients suffered from GERD for a long time and have symptoms that are disrupting daily life. These patients have already had complications like reflux esophagitis or they are perceived to be at high risk for complications
--- Patients suffering from 'recurrent, distressing GERD'
Having psychological and physical impact: Patients' GERD symptoms keep coming back and they start to become worried or anxious
--- Patients with 'inconveniencing GERD'
Having lower impact of the disease: Patients experience symptoms of GERD that are not continuous and preceived to be mostly related to lifestyle
Investigators concluded that greater recognition of GERD patients' different clinical and emotional needs, will facilitate more appropriate patient management.
Alan King, Director CLEAR Ideas, commented:
"These results provide a comprehensive picture of the GERD patient population. By considering the three patient groups in relation to choice of treatment, decisions can be better tailored to individual patient's needs."
The research was supported by AstraZeneca as part of ongoing work to improve knowledge and recognition in the GERD treatment population. The company's own proton pump inhibitor Nexium® (esomperazole) is approved for the treatment of patients with acid-related symptoms and diseases including gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) 3
Data has demonstrated that Nexium® can treat the range of patients suffering from GERD, including those who are frustrated by the disruption that the condition causes to their life4-11 For patients who present to the doctor with GERD symptoms6-11, effective acid suppression is needed.
GERD
Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.12
Symptoms can disrupt the physical, social and emotional wellbeing of many patients in spite of efforts to manage their condition.13
AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.
Nexium®
Nexium® is available in tablets (capsules in US) or intravenously in two strengths containing 20mg or 40mg esomeprazole3 Nexium® is particularly suitable for patients who present to the doctor with persistent, recurring GERD symptoms6-11 These patients have often suffered from symptoms for a long period and will have tried lifestyle changes, over the counter (OTC) medications and other treatments, but remain uncontrolled. http://www.purplepill.com
References
1. King A, MacDonald C, Orn C. Understanding gastroesophageal reflux disease (GERD): a patient segmentation analysis. Presented at Nordic Meeting of Gastroenterology 6-8 June, ReykjavÃk, Iceland
2. Alexander J, Orn C. Clinical characteristics of gastroesophageal reflux disease (GERD): a patient segmentation analysis. Presented at Nordic Meeting of Gastroenterology 6-8 June, ReykjavÃk, Iceland
3. Nexium Prescribing Information 20mg & 40mg, AstraZeneca
4. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patients who failed standard dose PPI versus switching to a different PPI. Gastroenterology 2004;126 Suppl 2:A37.
5. Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100:1914 - 22.
6. Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249 - 58.
7. Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656 - 65
8. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:926 - 35.
9. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27 - 34.
10. Lauritsen K, Junghard O, Eklund S, Wiklund I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Gastroenterology 2002;122:A200 (and associated poster).
11. Talley N Junghard O, Wiklund I. Improvement in health-related quality of life following esomeprazole treatment in patients with endoscopy-negative gastroesophageal reflux disease. J Gastroenterol Hepatol 2002;17 Suppl:A18.
12. Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R and the Global Consensus Group. The Montreal Definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900 - 20. 13. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract 2005;18:393 - 400. http://www.astrazeneca-us.com
View drug information on Nexium.
Global medic sondaj evidenþiazã nevoia de a ameliora gestionarea Gerd pacienþii - Global Physician Survey Highlights Need For Improved Management Of GERD Patients - articole medicale engleza - startsanatate